GPC3 and neoplasm: Taken together, these findings have largely dispelled our initial concerns regarding the potential for severe on-tumor and off-target side effects, such as cytokine storms, interstitial pneumonia, and hepatic impairment, resulting from combination therapy containing OHSV2-DSTEFAP5/CD3, because of the relatively low specificity of FAP and GPC3 target antigens, of course, suggesting that this novel strategy integrating different immune therapeutic drugs is worth further clinical development.